BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Bolt Biotherapeutics Inc. (BOLT) on Monday reported a loss of $15.9 million in its fourth quarter. The Redwood City, California-based company ...

Have you ever had a bolt snap in the middle of an important project? It can be stressful, but there are ways to get it out, ...

Season two has cut to black — or red, in the case of this finale. Speaking with The Hollywood Reporter, Erickson, Ben Stiller ...